Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option
against COVID-19. Because rapidly emerging virus mutants are becoming the next major …

Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat …

Antibodies are a potential therapy for severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), but the risk of the virus evolving to escape them remains unclear. Here we …

Antibodies elicited in response to infection undergo somatic mutation in germinal centers
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …

Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by
Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection …

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a
potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute …

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

Mutations in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) variants can compromise the effectiveness of therapeutic antibodies. Most clinical …

Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis
for coronavirus disease 2019 (COVID-19). However, ongoing evolution of severe acute …

Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future
protection of individuals and populations against SARS-CoV-2. Moreover, passively …